Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totalling 9,600 shares, a decrease of 62.2% from the September 15th total of 25,400 shares. Approximately 1.2% of the company’s stock are short sold. Based on an average daily trading volume, of 281,900 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 price target on shares of Addex Therapeutics in a research report on Wednesday, October 2nd.

Addex Therapeutics Stock Performance

NASDAQ:ADXN opened at $10.25 on Friday. The firm has a market cap of $10.87 million, a P/E ratio of -0.59 and a beta of 1.79. The firm has a 50-day simple moving average of $9.36 and a 200-day simple moving average of $10.50. Addex Therapeutics has a one year low of $5.00 and a one year high of $27.90.

Addex Therapeutics (NASDAQ:ADXN) last released its quarterly earnings results on Monday, September 30th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70). The firm had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.26 million. Addex Therapeutics had a negative net margin of 818.50% and a negative return on equity of 364.24%. On average, research analysts predict that Addex Therapeutics will post -0.36 EPS for the current fiscal year.

About Addex Therapeutics

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.